



## Q2 | 2022 Newsletter

Dear Friend of Navigation Sciences,

I am pleased to provide an update on the progress during the quarter of the NaviSci™ Intelligent Surgical System. Highlighting the quarter was the completion of the clinical trial, progress with the development of the NaviSci EndoMarker™, additional patent filings, and selection by the National Cancer Institute (NCI) to participate in its Investor Initiatives program.


### Clinical Feasibility Study Completed

In early Spring, we completed the 25-patient clinical trial that has been ongoing at Brigham & Women's hospital. The focus is now on analyzing the trial data and preparing the study for public disclosure. We plan to publish the study in a peer-reviewed journal and present the data at a significant healthcare conference, likely in the early 2023.

With the clinical trial completed, we are preparing for an FDA Pre-Submission meeting, which we expect to occur in the fourth quarter. The pre-submission session will provide an opportunity to define the regulatory pathway for the NaviSci System as well as receive Agency feedback on the clinical trial and other data we have assembled to date. We expect that the output of the meeting, along with the presentation/publication of the clinical trial data, will be essential value drivers for the company

### NaviSci EndoMarker™ Progress

We have made good progress with the SBIR/STTR-funded program to develop a bronchoscopy-based tissue marker, the NaviSci EndoMarker. The prototype is currently undergoing bench testing, with in vivo testing expected to begin in late 2022 or early 2023.



### New Patent Filings



As part of our ongoing efforts to enhance our intellectual property, we have filed a provisional application based on the NaviSci EndoMarker technology developed under the SBIR/STTR program grant. We also submitted a divisional application to expand the claims in our granted patents.

### NCI Investor Showcase Selection



In connection with our SBIR grant, we have been selected by the National Cancer Institute as a showcase company for the Institute's Investor Initiatives Program. Companies are selected for the program based on reviews by venture capital and corporate strategic investors for clinical need, technology, progress, and management.

Through the program, the company's information will be shared with the NCI's investor network, and the Institute provides support for participating in one of several industry conferences. The recognition and conference participation will support our fundraising efforts.

### LSI Emerging Medtech Summit Presentation

We also are participating in the RESI Boston conference, Sept. 21-23. If you plan to go, I hope you can attend our presentation.



Our Executive Summary has been updated to reflect Navigation Sciences' recent progress and can be downloaded from [here](#).

As always, thank you for your continued support.

Sincerely,

Alan Lucas, CEO  
alan.lucas@navisci.com  
[www.navigationsci.com](http://www.navigationsci.com)  
617.834.2829



[Navigation Sciences is on LinkedIn. Follow us for the latest, news, updates and upcoming events.](#)

[Visit Our Website](#)